Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi !

Palliative role of chemotherapy in patients with nonresectable cancer of the billiary system or advanced gallblader cancer (CROSBI ID 493958)

Prilog sa skupa u zborniku | sažetak izlaganja sa skupa | međunarodna recenzija

Dobrila-Dintinjana, Renata ; Štimac, Davor ; Ružić, Alen ; Dintinjana, Renata Palliative role of chemotherapy in patients with nonresectable cancer of the billiary system or advanced gallblader cancer // Supportive Care in Cancer / H.J.Senn (ur.). Philadelphia (PA): Springer, 2003. str. 414-415-x

Podaci o odgovornosti

Dobrila-Dintinjana, Renata ; Štimac, Davor ; Ružić, Alen ; Dintinjana, Renata

engleski

Palliative role of chemotherapy in patients with nonresectable cancer of the billiary system or advanced gallblader cancer

Introduction : Adenocarcinomas of the bile ducts (BSCa) and gallblader (GBCa) are highly malignant neoplasms with a very poor prognosis.Chemotherapy (cht) often plays only a palliative role and responses are transient without prolonged survival. Aim of the study : to evaluate effectivenes of gemcitabine (G) and cisplatin (C) combination protocol in achieveing Clinical Benefit Response (CBR) for patients (pts) with nonresectable BSCa and with advanced GBCa.Results : during four years period we curred 30 pts with BSCa and GBCa with mean age of 50+5, 4 years.There was 18 females with mean age of 48, 2+4, 6 years and 12 men with mean age 52, 6+4, 6 years.20 pts (66, 7%) had locally advanced disease and 10 pts (33, 3%)metastatic disease.Pts achieved G 1000 mg/m2 intravenous once per week for seven times.CP 100 mg/m2 iv was administered at day 1, 15, 29 and 43.Number of applicated cycles was 1-10 (median 4 cycles).Global response rate achieved 18 pts (60%), also as partial response rate (18 pts-60%).All pts (100%) achieved CBR.Pain measured at VAS scale before cht was 4, 8 ; and after first cycle 1, 6.Karnofsky Performance Status (KPS) before chemotherapy was 60% and after 1st cht cycle 80%.Median Duration Clinical Benefit was 22 weeks. Conclusion : This results indicate that the treatment of GBCa and BSCa with Gemcitabine and Ciplatinum is effective, well tolerated and leads to Clinical Benefit.We can also confirm that the role of cht is not only prolonging survival time but allso palliation and achieving better Qualitiy of Life.

palliative role; chemotherapy; nonresectable cacner; billiary system; advanced gallblader cancer

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o prilogu

414-415-x.

2003.

nije evidentirano

objavljeno

Podaci o matičnoj publikaciji

Supportive Care in Cancer

H.J.Senn

Philadelphia (PA): Springer

Podaci o skupu

15th MASCC International Symposium

predavanje

18.06.2003-21.06.2003

Berlin, Njemačka

Povezanost rada

Javno zdravstvo i zdravstvena zaštita